Poor and enantioselective bioavailability of naftopidil enantiomers is due to extensive and stereoselective metabolism in rat liver

[Display omitted] •Absorption is not the reason for the poor bioavailibilities of NAF enantiomers.•Extensive metabolism in the liver is the reason for the poor bioavailibilites.•Glucuronidation is the most important metabolic pathway for NAF enantiomers.•The glucuronidation of S(−)-NAF is faster, bu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of pharmaceutical and biomedical analysis 2017-01, Vol.132, p.165-172
Hauptverfasser: Liu, Xiawen, Zhu, Lijun, Huang, Biyun, Huang, Junjun, Cai, Yi, Zhu, Liu, Wu, Bo, Fu, Xiaojing, Zhang, Xingfei, Rong, Yi, Xiao, Qing, Guo, Jiewen, Li, Arong, Guo, Yifei, Yuan, Mu
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 172
container_issue
container_start_page 165
container_title Journal of pharmaceutical and biomedical analysis
container_volume 132
creator Liu, Xiawen
Zhu, Lijun
Huang, Biyun
Huang, Junjun
Cai, Yi
Zhu, Liu
Wu, Bo
Fu, Xiaojing
Zhang, Xingfei
Rong, Yi
Xiao, Qing
Guo, Jiewen
Li, Arong
Guo, Yifei
Yuan, Mu
description [Display omitted] •Absorption is not the reason for the poor bioavailibilities of NAF enantiomers.•Extensive metabolism in the liver is the reason for the poor bioavailibilites.•Glucuronidation is the most important metabolic pathway for NAF enantiomers.•The glucuronidation of S(−)-NAF is faster, but less than that of R(+)-NAF. Racemic naftopidil (NAF) is used to treat benign prostatic hyperplasia (BPH) and prostatic cancer (PCa). It exhibits greater efficacy but requires higher dose than other ɑ1-adrenoceptor blockers because of its poor bioavailability. It was previously shown that bioavailability of S(−)-NAF (14.5%) was twice that of R(+)-NAF (6.8%). The present study aimed to elucidate the major factors contributing to the poor and enantioselective bioavailability of NAF. First, absorption of NAF enantiomers was examined using a perfusated intestinal model. NAF enantiomers were found to be equally and highly permeable in all segments of the intestine. Second, the metabolites formed in different parts of the intestine and in bile were investigated. Glucuronidation of NAF enantiomers was found to occur primarily in the liver. Third, a new method consisting of ultra performance liquid chromatography coupled with triple-quadruple mass spectrometry (UPLC–MS/MS) was employed to quantify and calculate the pharmacokinetic parameters of NAF enantiomers and their glucuronides after the enantiomers were intravenously injected into rats. The amounts of R(+)-NAF glucuronide (R(+)-NAF-G) and S(−)-NAF glucuronide (S(−)-NAF-G) were six-fold higher than that of R(+)-NAF, and three-fold higher than that of S(−)-NAF. Glucuronidation of S(−)-NAF was faster than that of R(+)-NAF, but the conjugated amount was half of that of R(+)-NAF. Thus, bioavailability of S(−)-NAF was twice that of R(+)-NAF. In conclusion, extensive phase II metabolism in the liver significantly contributes to the low bioavailability of NAF enantiomers. Glucuronidation is the most important metabolic pathway for NAF enantiomers. Glucuronidation of S(−)-NAF is faster but occurs to a lesser extent than that of R(+)-NAF.
doi_str_mv 10.1016/j.jpba.2016.09.038
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1835438785</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0731708516307129</els_id><sourcerecordid>1835438785</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-cf8a66f19e829e8fcace647ce42c8d6e7d4bdd96a234b91bc84da11b6f451ed43</originalsourceid><addsrcrecordid>eNp9kM1q3DAUhUVJaaZpX6CLomU2diVblmTIJoT-QaBZNJCd0M81aJCtiaQZknVevDKThKy6uOgizvngfgh9oaSlhPJv23a7M7rt6t6SsSW9fIc2VIq-6Ti7O0EbInraCCKHU_Qx5y0hZKAj-4BOOyEYo2LYoKebGBPWi8Ow6KX4mCGALf4A2PioD9oHbXzw5RHHCS96KnHnnQ8v8RlSxj5jtwdcIoaHAkte2ysyF0jwhjhD0SYGn2fsF5x0waF-p0_o_aRDhs_P7xm6_fH979Wv5vrPz99Xl9eN7QdeGjtJzflER5BdnclqC5wJC6yz0nEQjhnnRq67npmRGiuZ05QaPrGBgmP9GTo_cncp3u8hFzX7bCEEvUDcZ0VlP7BeCjnUaHeM2hRzTjCpXfKzTo-KErXKV1u1ylerfEVGVeXX0tdn_t7M4F4rL7Zr4OIYgHrlwUNS2XpYLDifqiLlov8f_x_BsZp1</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1835438785</pqid></control><display><type>article</type><title>Poor and enantioselective bioavailability of naftopidil enantiomers is due to extensive and stereoselective metabolism in rat liver</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Liu, Xiawen ; Zhu, Lijun ; Huang, Biyun ; Huang, Junjun ; Cai, Yi ; Zhu, Liu ; Wu, Bo ; Fu, Xiaojing ; Zhang, Xingfei ; Rong, Yi ; Xiao, Qing ; Guo, Jiewen ; Li, Arong ; Guo, Yifei ; Yuan, Mu</creator><creatorcontrib>Liu, Xiawen ; Zhu, Lijun ; Huang, Biyun ; Huang, Junjun ; Cai, Yi ; Zhu, Liu ; Wu, Bo ; Fu, Xiaojing ; Zhang, Xingfei ; Rong, Yi ; Xiao, Qing ; Guo, Jiewen ; Li, Arong ; Guo, Yifei ; Yuan, Mu</creatorcontrib><description>[Display omitted] •Absorption is not the reason for the poor bioavailibilities of NAF enantiomers.•Extensive metabolism in the liver is the reason for the poor bioavailibilites.•Glucuronidation is the most important metabolic pathway for NAF enantiomers.•The glucuronidation of S(−)-NAF is faster, but less than that of R(+)-NAF. Racemic naftopidil (NAF) is used to treat benign prostatic hyperplasia (BPH) and prostatic cancer (PCa). It exhibits greater efficacy but requires higher dose than other ɑ1-adrenoceptor blockers because of its poor bioavailability. It was previously shown that bioavailability of S(−)-NAF (14.5%) was twice that of R(+)-NAF (6.8%). The present study aimed to elucidate the major factors contributing to the poor and enantioselective bioavailability of NAF. First, absorption of NAF enantiomers was examined using a perfusated intestinal model. NAF enantiomers were found to be equally and highly permeable in all segments of the intestine. Second, the metabolites formed in different parts of the intestine and in bile were investigated. Glucuronidation of NAF enantiomers was found to occur primarily in the liver. Third, a new method consisting of ultra performance liquid chromatography coupled with triple-quadruple mass spectrometry (UPLC–MS/MS) was employed to quantify and calculate the pharmacokinetic parameters of NAF enantiomers and their glucuronides after the enantiomers were intravenously injected into rats. The amounts of R(+)-NAF glucuronide (R(+)-NAF-G) and S(−)-NAF glucuronide (S(−)-NAF-G) were six-fold higher than that of R(+)-NAF, and three-fold higher than that of S(−)-NAF. Glucuronidation of S(−)-NAF was faster than that of R(+)-NAF, but the conjugated amount was half of that of R(+)-NAF. Thus, bioavailability of S(−)-NAF was twice that of R(+)-NAF. In conclusion, extensive phase II metabolism in the liver significantly contributes to the low bioavailability of NAF enantiomers. Glucuronidation is the most important metabolic pathway for NAF enantiomers. Glucuronidation of S(−)-NAF is faster but occurs to a lesser extent than that of R(+)-NAF.</description><identifier>ISSN: 0731-7085</identifier><identifier>EISSN: 1873-264X</identifier><identifier>DOI: 10.1016/j.jpba.2016.09.038</identifier><identifier>PMID: 27744175</identifier><language>eng</language><publisher>England: Elsevier B.V</publisher><subject>Animals ; Biological Availability ; Chromatography, High Pressure Liquid ; Female ; Glucuronidation ; Glucuronides - metabolism ; Infusions, Intravenous ; Intestinal absorption ; Intestines - drug effects ; Liver - drug effects ; Liver - metabolism ; Male ; Mass Spectrometry ; Microsomes, Liver - metabolism ; Naftopidil enantiomers ; Naphthalenes - metabolism ; Naphthalenes - pharmacokinetics ; Pharmacokinetics ; Piperazines - metabolism ; Piperazines - pharmacokinetics ; Prostatic Hyperplasia - drug therapy ; Quality Control ; Rats ; Rats, Sprague-Dawley ; Reproducibility of Results ; Stereoisomerism ; Tandem Mass Spectrometry ; Temperature ; UPLC–MS/MS</subject><ispartof>Journal of pharmaceutical and biomedical analysis, 2017-01, Vol.132, p.165-172</ispartof><rights>2016 Elsevier B.V.</rights><rights>Copyright © 2016 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-cf8a66f19e829e8fcace647ce42c8d6e7d4bdd96a234b91bc84da11b6f451ed43</citedby><cites>FETCH-LOGICAL-c356t-cf8a66f19e829e8fcace647ce42c8d6e7d4bdd96a234b91bc84da11b6f451ed43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jpba.2016.09.038$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27744175$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liu, Xiawen</creatorcontrib><creatorcontrib>Zhu, Lijun</creatorcontrib><creatorcontrib>Huang, Biyun</creatorcontrib><creatorcontrib>Huang, Junjun</creatorcontrib><creatorcontrib>Cai, Yi</creatorcontrib><creatorcontrib>Zhu, Liu</creatorcontrib><creatorcontrib>Wu, Bo</creatorcontrib><creatorcontrib>Fu, Xiaojing</creatorcontrib><creatorcontrib>Zhang, Xingfei</creatorcontrib><creatorcontrib>Rong, Yi</creatorcontrib><creatorcontrib>Xiao, Qing</creatorcontrib><creatorcontrib>Guo, Jiewen</creatorcontrib><creatorcontrib>Li, Arong</creatorcontrib><creatorcontrib>Guo, Yifei</creatorcontrib><creatorcontrib>Yuan, Mu</creatorcontrib><title>Poor and enantioselective bioavailability of naftopidil enantiomers is due to extensive and stereoselective metabolism in rat liver</title><title>Journal of pharmaceutical and biomedical analysis</title><addtitle>J Pharm Biomed Anal</addtitle><description>[Display omitted] •Absorption is not the reason for the poor bioavailibilities of NAF enantiomers.•Extensive metabolism in the liver is the reason for the poor bioavailibilites.•Glucuronidation is the most important metabolic pathway for NAF enantiomers.•The glucuronidation of S(−)-NAF is faster, but less than that of R(+)-NAF. Racemic naftopidil (NAF) is used to treat benign prostatic hyperplasia (BPH) and prostatic cancer (PCa). It exhibits greater efficacy but requires higher dose than other ɑ1-adrenoceptor blockers because of its poor bioavailability. It was previously shown that bioavailability of S(−)-NAF (14.5%) was twice that of R(+)-NAF (6.8%). The present study aimed to elucidate the major factors contributing to the poor and enantioselective bioavailability of NAF. First, absorption of NAF enantiomers was examined using a perfusated intestinal model. NAF enantiomers were found to be equally and highly permeable in all segments of the intestine. Second, the metabolites formed in different parts of the intestine and in bile were investigated. Glucuronidation of NAF enantiomers was found to occur primarily in the liver. Third, a new method consisting of ultra performance liquid chromatography coupled with triple-quadruple mass spectrometry (UPLC–MS/MS) was employed to quantify and calculate the pharmacokinetic parameters of NAF enantiomers and their glucuronides after the enantiomers were intravenously injected into rats. The amounts of R(+)-NAF glucuronide (R(+)-NAF-G) and S(−)-NAF glucuronide (S(−)-NAF-G) were six-fold higher than that of R(+)-NAF, and three-fold higher than that of S(−)-NAF. Glucuronidation of S(−)-NAF was faster than that of R(+)-NAF, but the conjugated amount was half of that of R(+)-NAF. Thus, bioavailability of S(−)-NAF was twice that of R(+)-NAF. In conclusion, extensive phase II metabolism in the liver significantly contributes to the low bioavailability of NAF enantiomers. Glucuronidation is the most important metabolic pathway for NAF enantiomers. Glucuronidation of S(−)-NAF is faster but occurs to a lesser extent than that of R(+)-NAF.</description><subject>Animals</subject><subject>Biological Availability</subject><subject>Chromatography, High Pressure Liquid</subject><subject>Female</subject><subject>Glucuronidation</subject><subject>Glucuronides - metabolism</subject><subject>Infusions, Intravenous</subject><subject>Intestinal absorption</subject><subject>Intestines - drug effects</subject><subject>Liver - drug effects</subject><subject>Liver - metabolism</subject><subject>Male</subject><subject>Mass Spectrometry</subject><subject>Microsomes, Liver - metabolism</subject><subject>Naftopidil enantiomers</subject><subject>Naphthalenes - metabolism</subject><subject>Naphthalenes - pharmacokinetics</subject><subject>Pharmacokinetics</subject><subject>Piperazines - metabolism</subject><subject>Piperazines - pharmacokinetics</subject><subject>Prostatic Hyperplasia - drug therapy</subject><subject>Quality Control</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Reproducibility of Results</subject><subject>Stereoisomerism</subject><subject>Tandem Mass Spectrometry</subject><subject>Temperature</subject><subject>UPLC–MS/MS</subject><issn>0731-7085</issn><issn>1873-264X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM1q3DAUhUVJaaZpX6CLomU2diVblmTIJoT-QaBZNJCd0M81aJCtiaQZknVevDKThKy6uOgizvngfgh9oaSlhPJv23a7M7rt6t6SsSW9fIc2VIq-6Ti7O0EbInraCCKHU_Qx5y0hZKAj-4BOOyEYo2LYoKebGBPWi8Ow6KX4mCGALf4A2PioD9oHbXzw5RHHCS96KnHnnQ8v8RlSxj5jtwdcIoaHAkte2ysyF0jwhjhD0SYGn2fsF5x0waF-p0_o_aRDhs_P7xm6_fH979Wv5vrPz99Xl9eN7QdeGjtJzflER5BdnclqC5wJC6yz0nEQjhnnRq67npmRGiuZ05QaPrGBgmP9GTo_cncp3u8hFzX7bCEEvUDcZ0VlP7BeCjnUaHeM2hRzTjCpXfKzTo-KErXKV1u1ylerfEVGVeXX0tdn_t7M4F4rL7Zr4OIYgHrlwUNS2XpYLDifqiLlov8f_x_BsZp1</recordid><startdate>20170105</startdate><enddate>20170105</enddate><creator>Liu, Xiawen</creator><creator>Zhu, Lijun</creator><creator>Huang, Biyun</creator><creator>Huang, Junjun</creator><creator>Cai, Yi</creator><creator>Zhu, Liu</creator><creator>Wu, Bo</creator><creator>Fu, Xiaojing</creator><creator>Zhang, Xingfei</creator><creator>Rong, Yi</creator><creator>Xiao, Qing</creator><creator>Guo, Jiewen</creator><creator>Li, Arong</creator><creator>Guo, Yifei</creator><creator>Yuan, Mu</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170105</creationdate><title>Poor and enantioselective bioavailability of naftopidil enantiomers is due to extensive and stereoselective metabolism in rat liver</title><author>Liu, Xiawen ; Zhu, Lijun ; Huang, Biyun ; Huang, Junjun ; Cai, Yi ; Zhu, Liu ; Wu, Bo ; Fu, Xiaojing ; Zhang, Xingfei ; Rong, Yi ; Xiao, Qing ; Guo, Jiewen ; Li, Arong ; Guo, Yifei ; Yuan, Mu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-cf8a66f19e829e8fcace647ce42c8d6e7d4bdd96a234b91bc84da11b6f451ed43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Animals</topic><topic>Biological Availability</topic><topic>Chromatography, High Pressure Liquid</topic><topic>Female</topic><topic>Glucuronidation</topic><topic>Glucuronides - metabolism</topic><topic>Infusions, Intravenous</topic><topic>Intestinal absorption</topic><topic>Intestines - drug effects</topic><topic>Liver - drug effects</topic><topic>Liver - metabolism</topic><topic>Male</topic><topic>Mass Spectrometry</topic><topic>Microsomes, Liver - metabolism</topic><topic>Naftopidil enantiomers</topic><topic>Naphthalenes - metabolism</topic><topic>Naphthalenes - pharmacokinetics</topic><topic>Pharmacokinetics</topic><topic>Piperazines - metabolism</topic><topic>Piperazines - pharmacokinetics</topic><topic>Prostatic Hyperplasia - drug therapy</topic><topic>Quality Control</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Reproducibility of Results</topic><topic>Stereoisomerism</topic><topic>Tandem Mass Spectrometry</topic><topic>Temperature</topic><topic>UPLC–MS/MS</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, Xiawen</creatorcontrib><creatorcontrib>Zhu, Lijun</creatorcontrib><creatorcontrib>Huang, Biyun</creatorcontrib><creatorcontrib>Huang, Junjun</creatorcontrib><creatorcontrib>Cai, Yi</creatorcontrib><creatorcontrib>Zhu, Liu</creatorcontrib><creatorcontrib>Wu, Bo</creatorcontrib><creatorcontrib>Fu, Xiaojing</creatorcontrib><creatorcontrib>Zhang, Xingfei</creatorcontrib><creatorcontrib>Rong, Yi</creatorcontrib><creatorcontrib>Xiao, Qing</creatorcontrib><creatorcontrib>Guo, Jiewen</creatorcontrib><creatorcontrib>Li, Arong</creatorcontrib><creatorcontrib>Guo, Yifei</creatorcontrib><creatorcontrib>Yuan, Mu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pharmaceutical and biomedical analysis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, Xiawen</au><au>Zhu, Lijun</au><au>Huang, Biyun</au><au>Huang, Junjun</au><au>Cai, Yi</au><au>Zhu, Liu</au><au>Wu, Bo</au><au>Fu, Xiaojing</au><au>Zhang, Xingfei</au><au>Rong, Yi</au><au>Xiao, Qing</au><au>Guo, Jiewen</au><au>Li, Arong</au><au>Guo, Yifei</au><au>Yuan, Mu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Poor and enantioselective bioavailability of naftopidil enantiomers is due to extensive and stereoselective metabolism in rat liver</atitle><jtitle>Journal of pharmaceutical and biomedical analysis</jtitle><addtitle>J Pharm Biomed Anal</addtitle><date>2017-01-05</date><risdate>2017</risdate><volume>132</volume><spage>165</spage><epage>172</epage><pages>165-172</pages><issn>0731-7085</issn><eissn>1873-264X</eissn><abstract>[Display omitted] •Absorption is not the reason for the poor bioavailibilities of NAF enantiomers.•Extensive metabolism in the liver is the reason for the poor bioavailibilites.•Glucuronidation is the most important metabolic pathway for NAF enantiomers.•The glucuronidation of S(−)-NAF is faster, but less than that of R(+)-NAF. Racemic naftopidil (NAF) is used to treat benign prostatic hyperplasia (BPH) and prostatic cancer (PCa). It exhibits greater efficacy but requires higher dose than other ɑ1-adrenoceptor blockers because of its poor bioavailability. It was previously shown that bioavailability of S(−)-NAF (14.5%) was twice that of R(+)-NAF (6.8%). The present study aimed to elucidate the major factors contributing to the poor and enantioselective bioavailability of NAF. First, absorption of NAF enantiomers was examined using a perfusated intestinal model. NAF enantiomers were found to be equally and highly permeable in all segments of the intestine. Second, the metabolites formed in different parts of the intestine and in bile were investigated. Glucuronidation of NAF enantiomers was found to occur primarily in the liver. Third, a new method consisting of ultra performance liquid chromatography coupled with triple-quadruple mass spectrometry (UPLC–MS/MS) was employed to quantify and calculate the pharmacokinetic parameters of NAF enantiomers and their glucuronides after the enantiomers were intravenously injected into rats. The amounts of R(+)-NAF glucuronide (R(+)-NAF-G) and S(−)-NAF glucuronide (S(−)-NAF-G) were six-fold higher than that of R(+)-NAF, and three-fold higher than that of S(−)-NAF. Glucuronidation of S(−)-NAF was faster than that of R(+)-NAF, but the conjugated amount was half of that of R(+)-NAF. Thus, bioavailability of S(−)-NAF was twice that of R(+)-NAF. In conclusion, extensive phase II metabolism in the liver significantly contributes to the low bioavailability of NAF enantiomers. Glucuronidation is the most important metabolic pathway for NAF enantiomers. Glucuronidation of S(−)-NAF is faster but occurs to a lesser extent than that of R(+)-NAF.</abstract><cop>England</cop><pub>Elsevier B.V</pub><pmid>27744175</pmid><doi>10.1016/j.jpba.2016.09.038</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0731-7085
ispartof Journal of pharmaceutical and biomedical analysis, 2017-01, Vol.132, p.165-172
issn 0731-7085
1873-264X
language eng
recordid cdi_proquest_miscellaneous_1835438785
source MEDLINE; ScienceDirect Journals (5 years ago - present)
subjects Animals
Biological Availability
Chromatography, High Pressure Liquid
Female
Glucuronidation
Glucuronides - metabolism
Infusions, Intravenous
Intestinal absorption
Intestines - drug effects
Liver - drug effects
Liver - metabolism
Male
Mass Spectrometry
Microsomes, Liver - metabolism
Naftopidil enantiomers
Naphthalenes - metabolism
Naphthalenes - pharmacokinetics
Pharmacokinetics
Piperazines - metabolism
Piperazines - pharmacokinetics
Prostatic Hyperplasia - drug therapy
Quality Control
Rats
Rats, Sprague-Dawley
Reproducibility of Results
Stereoisomerism
Tandem Mass Spectrometry
Temperature
UPLC–MS/MS
title Poor and enantioselective bioavailability of naftopidil enantiomers is due to extensive and stereoselective metabolism in rat liver
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T12%3A49%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Poor%20and%20enantioselective%20bioavailability%20of%20naftopidil%20enantiomers%20is%20due%20to%20extensive%20and%20stereoselective%20metabolism%20in%20rat%20liver&rft.jtitle=Journal%20of%20pharmaceutical%20and%20biomedical%20analysis&rft.au=Liu,%20Xiawen&rft.date=2017-01-05&rft.volume=132&rft.spage=165&rft.epage=172&rft.pages=165-172&rft.issn=0731-7085&rft.eissn=1873-264X&rft_id=info:doi/10.1016/j.jpba.2016.09.038&rft_dat=%3Cproquest_cross%3E1835438785%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1835438785&rft_id=info:pmid/27744175&rft_els_id=S0731708516307129&rfr_iscdi=true